Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.34 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28238201 | 0.88 | DDB1 (0.32) | DDB1CRBNKDM4ELMNATSHR | |
| SCHEMBL4572618 | 0.83 | DDB1 (0.31) | DDB1CRBN | |
| SCHEMBL8466043 | 0.78 | KDM4E (0.30) | KDM4ELMNA | |
| SCHEMBL423425 | 0.74 | PTGS2 (0.39) | DDB1CRBNLMNATSHR | |
| SCHEMBL11738688 | 0.74 | ALDH1A1 (0.34) | DDB1CRBNKDM4ELMNATSHR | |
| SCHEMBL2968803 | 0.74 | MAP2K7 (0.43) | TDP1KDM4ETSHR | |
| SCHEMBL4572616 | 0.72 | — | — | |
| SCHEMBL28546132 | 0.72 | ALDH1A1 (0.35) | DDB1CRBNKDM4ELMNA | |
| SCHEMBL27788661 | 0.71 | TSHR (0.37) | DDB1CRBNKDM4ELMNATSHR | |
| SCHEMBL9621322 | 0.70 | RAB9A (0.43) | TDP1KDM4ELMNATSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | ELCELYX THERAPEUTICS, INC. (US) | 2013-11-14 | — | — | US | disclosed |
| WO-2012054527-A2 | CHEMOSENSORY RECEPTOR LIGAND-BASED THERAPIES | ELCELYX THERAPEUTICS, INC. (US) | 2012-04-26 | — | — | WO | disclosed |
| EP-2049509-B1 | NEW FURYL THIOALKANALS USEFUL IN THE FLAVOR INDUSTRY | FIRMENICH & CIE (CH) | 2011-10-26 | — | — | EP | disclosed |
| US-7989013-B2 | Furyl thioalkanals useful in the flavor industry | FIRMENICH SA (CH) | 2011-08-02 | — | — | US | disclosed |
| US-20090232935-A1 | NEW FURYL THIOALKANALS USEFUL IN THE FLAVOR INDUSTRY | FIRMENICH SA (CH) | 2009-09-17 | — | — | US | disclosed |
| EP-2049509-A2 | NEW FURYL THIOALKANALS USEFUL IN THE FLAVOR INDUSTRY | FIRMENICH SA (CH) | 2009-04-22 | — | — | EP | disclosed |
| WO-2008015638-A2 | NEW FURYL THIOALKANALS USEFUL IN THE FLAVOR INDUSTRY | FIRMENICH SA (CH) | 2008-02-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130303466-A1 | Chemosensory Receptor Ligand-Based Therapies | GPR119, TAS1R2, TAS2R1 | TDP1 3786/4885DDB1 1640/4885CRBN 1037/4885 |
| US-20090232935-A1 | NEW FURYL THIOALKANALS USEFUL IN THE FLAVOR INDUSTRY | TAS2R40, TAS2R10, TAS2R5 | TDP1 807/4885DDB1 2332/4885CRBN 1636/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.